Zelira Therapeutics Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZLDAF research report →
Companywww.zeliratx.com
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes.
- CEO
- Oludare Odumosu
- IPO
- 2017
- Employees
- 8
- HQ
- Perth, WA, AU
Price Chart
Valuation
- Market Cap
- $4.16M
- P/E
- -1.60
- P/S
- 9081.80
- P/B
- -1.30
- EV/EBITDA
- -1.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -122587.02%
- Op Margin
- -663833.74%
- Net Margin
- -553873.59%
- ROE
- 56.41%
- ROIC
- 202.34%
Growth & Income
- Revenue
- $656 · -99.31%
- Net Income
- $-3,627,872 · 90.08%
- EPS
- $-0.32 · 90.06%
- Op Income
- $-3,952,189
- FCF YoY
- -11.81%
Performance & Tape
- 52W High
- $0.42
- 52W Low
- $0.20
- 50D MA
- $0.36
- 200D MA
- $0.29
- Beta
- 0.56
- Avg Volume
- 22
Get TickerSpark's AI analysis on ZLDAF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ZLDAF Coverage
We haven't published any research on ZLDAF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ZLDAF Report →